Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

Kazimierz Groen; Fredrik H. Schjesvold; Bronno Van Der Holt; Mark David Levin; Maarten R. Seefat; Markus Hansson; Maria B.L. Leys; Josien C. Regelink; Anders Waage; Damian Szatkowski; Per Axelsson; Trung Hieu Do; Asta Svirskaite; Ellen Van Der Spek; Einar Haukas; Dorota Knut-Bojanowska; Paula F. Ypma; Cecilie H. Blimark; Ulf Henrik Mellqvist; Niels W.C.J. Van De Donk; Pieter Sonneveld; Anja Klostergaard; Annette J. Vangsted; Niels Abildgaard; Sonja Zweegman

doi:10.1097/HS9.0000000000000940

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

Kazimierz Groen^*, Fredrik H. Schjesvold, Bronno Van Der Holt, Mark David Levin, Maarten R. Seefat, Markus Hansson, Maria B.L. Leys, Josien C. Regelink, Anders Waage, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Asta Svirskaite, Ellen Van Der Spek, Einar Haukas, Dorota Knut-Bojanowska, Paula F. Ypma, Cecilie H. Blimark, Ulf Henrik Mellqvist, Niels W.C.J. Van De DonkPieter Sonneveld, Anja Klostergaard, Annette J. Vangsted, Niels Abildgaard, Sonja Zweegman

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Letter › peer review

1 Citationer (Scopus)

7 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	E940
Tidsskrift	HemaSphere
Vol/bind	7
Udgave nummer	9
Antal sider	4
ISSN	2572-9241
DOI	https://doi.org/10.1097/HS9.0000000000000940
Status	Udgivet - 2023

Bibliografisk note

Funding Information:
This study had partial research funding from Takeda Pharmaceutical Company Limited.

Adgang til dokumentet

10.1097/HS9.0000000000000940Licens: CC BY-ND

FulltextForlagets udgivne version, 709 KBLicens: CC BY-ND

Citationsformater

Groen, K., Schjesvold, F. H., Van Der Holt, B., Levin, M. D., Seefat, M. R., Hansson, M., Leys, M. B. L., Regelink, J. C., Waage, A., Szatkowski, D., Axelsson, P., Hieu Do, T., Svirskaite, A., Van Der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C. H., Mellqvist, U. H., ... Zweegman, S. (2023). Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13. HemaSphere, 7(9), Artikel E940. https://doi.org/10.1097/HS9.0000000000000940

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13. / Groen, Kazimierz; Schjesvold, Fredrik H.; Van Der Holt, Bronno et al.
I: HemaSphere, Bind 7, Nr. 9, E940, 2023.

Publikation: Bidrag til tidsskrift › Letter › peer review

Groen, K, Schjesvold, FH, Van Der Holt, B, Levin, MD, Seefat, MR, Hansson, M, Leys, MBL, Regelink, JC, Waage, A, Szatkowski, D, Axelsson, P, Hieu Do, T, Svirskaite, A, Van Der Spek, E, Haukas, E, Knut-Bojanowska, D, Ypma, PF, Blimark, CH, Mellqvist, UH, Van De Donk, NWCJ, Sonneveld, P, Klostergaard, A, Vangsted, AJ, Abildgaard, N & Zweegman, S 2023, 'Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13', HemaSphere, bind 7, nr. 9, E940. https://doi.org/10.1097/HS9.0000000000000940

@article{9c66efccba894c65ba1db725da31ef1e,

title = "Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13",

author = "Kazimierz Groen and Schjesvold, {Fredrik H.} and {Van Der Holt}, Bronno and Levin, {Mark David} and Seefat, {Maarten R.} and Markus Hansson and Leys, {Maria B.L.} and Regelink, {Josien C.} and Anders Waage and Damian Szatkowski and Per Axelsson and {Hieu Do}, Trung and Asta Svirskaite and {Van Der Spek}, Ellen and Einar Haukas and Dorota Knut-Bojanowska and Ypma, {Paula F.} and Blimark, {Cecilie H.} and Mellqvist, {Ulf Henrik} and {Van De Donk}, {Niels W.C.J.} and Pieter Sonneveld and Anja Klostergaard and Vangsted, {Annette J.} and Niels Abildgaard and Sonja Zweegman",

note = "Funding Information: This study had partial research funding from Takeda Pharmaceutical Company Limited.",

year = "2023",

doi = "10.1097/HS9.0000000000000940",

language = "English",

volume = "7",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Lippincott, Williams & Wilkins",

number = "9",

}

TY - JOUR

T1 - Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients

T2 - Long-term Results of HOVON-126/NMSG 21.13

AU - Groen, Kazimierz

AU - Schjesvold, Fredrik H.

AU - Van Der Holt, Bronno

AU - Levin, Mark David

AU - Seefat, Maarten R.

AU - Hansson, Markus

AU - Leys, Maria B.L.

AU - Regelink, Josien C.

AU - Waage, Anders

AU - Szatkowski, Damian

AU - Axelsson, Per

AU - Hieu Do, Trung

AU - Svirskaite, Asta

AU - Van Der Spek, Ellen

AU - Haukas, Einar

AU - Knut-Bojanowska, Dorota

AU - Ypma, Paula F.

AU - Blimark, Cecilie H.

AU - Mellqvist, Ulf Henrik

AU - Van De Donk, Niels W.C.J.

AU - Sonneveld, Pieter

AU - Klostergaard, Anja

AU - Vangsted, Annette J.

AU - Abildgaard, Niels

AU - Zweegman, Sonja

N1 - Funding Information: This study had partial research funding from Takeda Pharmaceutical Company Limited.

PY - 2023

Y1 - 2023

U2 - 10.1097/HS9.0000000000000940

DO - 10.1097/HS9.0000000000000940

M3 - Letter

C2 - 37663673

AN - SCOPUS:85171177792

SN - 2572-9241

VL - 7

JO - HemaSphere

JF - HemaSphere

IS - 9

M1 - E940

ER -